EP1526910A2 - Filtermaterial f r toxine, bakterien, viren und andere physi ologische schadstoffe - Google Patents
Filtermaterial f r toxine, bakterien, viren und andere physi ologische schadstoffeInfo
- Publication number
- EP1526910A2 EP1526910A2 EP03737999A EP03737999A EP1526910A2 EP 1526910 A2 EP1526910 A2 EP 1526910A2 EP 03737999 A EP03737999 A EP 03737999A EP 03737999 A EP03737999 A EP 03737999A EP 1526910 A2 EP1526910 A2 EP 1526910A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- filter material
- material according
- aryl
- alkyl
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000463 material Substances 0.000 title claims abstract description 39
- 241000700605 Viruses Species 0.000 title claims abstract description 8
- 239000003053 toxin Substances 0.000 title claims abstract description 8
- 231100000765 toxin Toxicity 0.000 title claims abstract description 8
- 108700012359 toxins Proteins 0.000 title claims abstract description 8
- 241000894006 Bacteria Species 0.000 title claims abstract description 7
- 239000000126 substance Substances 0.000 title abstract description 9
- 230000001951 hemoperfusion Effects 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 210000002381 plasma Anatomy 0.000 claims abstract description 3
- 210000002700 urine Anatomy 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000003344 environmental pollutant Substances 0.000 claims description 9
- 231100000719 pollutant Toxicity 0.000 claims description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 150000003460 sulfonic acids Chemical class 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 150000003983 crown ethers Chemical class 0.000 claims description 6
- 229940097362 cyclodextrins Drugs 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 238000007669 thermal treatment Methods 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229910001930 tungsten oxide Inorganic materials 0.000 claims description 2
- 239000010457 zeolite Substances 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000003993 interaction Effects 0.000 description 9
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- GQPLZGRPYWLBPW-UHFFFAOYSA-N calix[4]arene Chemical compound C1C(C=2)=CC=CC=2CC(C=2)=CC=CC=2CC(C=2)=CC=CC=2CC2=CC=CC1=C2 GQPLZGRPYWLBPW-UHFFFAOYSA-N 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- -1 Ri = H Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- SYJFEGQWDCRVNX-UHFFFAOYSA-N diquat Chemical compound C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 SYJFEGQWDCRVNX-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229940124547 specific antidotes Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/203—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/206—Viruses
Definitions
- the invention relates to a filter material for toxins, bacteria, viruses and other physiological pollutants, which can be used in hemoperfusion to rid the blood of such pollutants.
- the filter material is based on compounds from the class of calixarenes and reosrcinarene.
- Hemoperfusion is one of the (most effective measures for extracorporeal elimination of toxins and pollutants.
- hemoperfusion In contrast to hemodialysis, hemoperfusion is able to eliminate lipophilic substances that are not suitable for dialysis from the blood. However, hemoperfusion is usually superior to substances capable of dialysis. An important side effect, which has not yet been eliminated, is the undesired adsorption of throinocytes, which can be in a range up to about 40%.
- a filter material which consists of a compound of the general formula I
- R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with • 1 to 12 carbon atoms, amino acids, sugar or crown ether,
- Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfonamides, amino acids, sugars, crown ethers, cyclodextrins, purine bases or pyridine bases,
- R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms or amino acids
- Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfona ide, amino acids, sugar, crown ethers, cyclodextrins, purine bases or pyrimidine bases,
- R 2 * alkyl or aryl
- R 3 and 4 0, where R 3 and R are bridged together via methylene, ethylene or quinoxaline
- the designated aromatic systems can be any heteroatoms, e.g. B. 0, S, N, have.
- the peculiarity of the solution according to the invention is based on the fact that the macromolecules used from the group of the calixarenes and resorcinarenes are easily accessible synthetically and can be modified universally. So you can open them up. Optimize various requirements regarding the substance classes of the toxins to be eliminated. It is particularly interesting in view of the fact that a large number of substances have hitherto been insufficiently eliminated, for example B. Paraquat and Diquat.
- any matrices known from the prior art can be used as the carrier.
- the filter material it is also possible for the filter material to contain or consist of biomatrixes such as cotton or cellulose.
- Micelle formers or compounds from the group cyclodextrins are preferably contained as additives.
- cyclodextrins are significantly more polar and hydrophilic than calixarenes or resorcinarenes, which means that. certain applications a higher hydrophilicity of the filter material than can be realized.
- the calixarenes or resorcinarenes of the general formulas I and II must be modified depending on the pollutant to be eliminated.
- the modification takes place from the point of view of optimizing the interaction between the filter material and the relevant target molecule, ie. H. the pollutant.
- hydrophilic groups in the compounds are necessary to ensure water solubility.
- modification options of the filter material are to be mentioned here only by way of example in order to implement special applications. This includes, on the one hand, modifying the filter material with sugars that can interact with bacteria, making them accessible for hemoperfusion, so that they can be filtered out of physiological fluids. By modifying the filter material with amino acids, an interaction with viruses can also be made possible, so that these can also be separated using hemoperfusion.
- the filter material provides that the compound of the general formulas I and II are modified with antibodies. This enables the rapid elimination of antigens due to antigen-antibody interactions. With aggressive viruses in particular, there is the possibility of removing antigens from the organism until the immune system has stabilized.
- the filter material is based on the fact that the compounds of the general formulas I and II have a high temperature resistance, which can be exploited in such a way that recyclable filter materials can be provided.
- Appropriate thermal treatment thermally decomposes the pollutants eliminated from the blood, while the compounds of the general formulas I and II contained in the filter material remain stable. Such thermal treatments are preferably carried out above 300 ° C. Compared to the filter materials known from the prior art, the inventive materials thus have a significantly higher thermal stability.
- the filter material is preferably integrated into common filter devices. This includes, for example, cartridges, frits, disks or membranes.
- the filter material according to the invention is preferably used for the hemoperfusion of physiological liquids.
- Blood, plasma or urine are only examples of physiological fluids.
- the subject according to the invention is intended to be explained in more detail with reference to the following figure and the examples, without restricting it to the exemplary embodiments mentioned.
- 1 shows a schematic structural model of the tetrasulfonic acid calix [4] arene-paraquat complex.
- a paraquat molecule shows the incorporation of a paraquat molecule into a tetrasulfonic acid calix [4] arene system.
- the paraquat is bound to the filter material via different interactions. This includes a cation-OH interaction 1, a cation- ⁇ interaction 2, a CH- ⁇ interaction 3 and a ⁇ - ⁇ interaction 4.
- the complex formation constant is very large and can be in the range 10 5 are up to 10 ⁇ . This means that paraquat is stored irreversibly and can thus be permanently removed from the bloodstream, for example by hemoperfusion.
- the sulfuric acid is added all at once to the calix [4] arene in a 100 ml three-necked flask with gas inlet and outlet devices.
- the apparatus is flushed with argon and the reaction mixture is stirred at 80 ° C. for about 4 hours.
- the course of the reaction is followed by taking a sample and checking the solubility in water. If the mixture is soluble in water without a residue, the reaction is stopped.
- the crude product is filtered off with a glass frit (4 A), dissolved in methanol (in order to remove remaining sulfuric acid) and precipitated with ethyl acetate.
- the white precipitate is dried in an oil pump vacuum-
- Paraquat is a very effective contact herbicide and as such has been widely used for many decades.
- the toxic effect on plants is based on the inhibition of photosynthesis by the formation of radical intermediates which prevent the NADP reduction. This hinders the transmission of energy. It is 'non-toxic to rapidly oxygen, reduced well waser- soluble compounds, whereby it is a good way to carry out the control of weeds in time selectively and relatively umweitschonend' in the field in the presence of light and.
- Paraquat has repeatedly resulted in numerous acute and chronic poisonings in humans when used in agriculture or when attempting suicide. Symptoms such as eye damage, kidney and liver damage, gastritis and lung diseases occur until death from suffocation. Therapeutic measures are limited because there is no specific antidote. Adsorption on activated carbon or carbon filters is weak, which is why stronger interactions with adsorbents are sought.
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226099A DE10226099A1 (de) | 2002-06-12 | 2002-06-12 | Filtermaterial für Toxine, Bakterien, Viren und andere physiologische Schadstoffe |
| DE10226099 | 2002-06-12 | ||
| PCT/EP2003/005957 WO2003105990A2 (de) | 2002-06-12 | 2003-06-06 | Filtermaterial für toxine, bakterien, viren und andere physiologische schadstoffe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1526910A2 true EP1526910A2 (de) | 2005-05-04 |
Family
ID=29718988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03737999A Withdrawn EP1526910A2 (de) | 2002-06-12 | 2003-06-06 | Filtermaterial f r toxine, bakterien, viren und andere physi ologische schadstoffe |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1526910A2 (de) |
| AU (1) | AU2003245917A1 (de) |
| DE (1) | DE10226099A1 (de) |
| WO (1) | WO2003105990A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989008092A1 (en) * | 1988-02-29 | 1989-09-08 | The Flinders University Of South Australia | Removal of organic compounds from fluids |
| US5312837A (en) * | 1991-01-29 | 1994-05-17 | Genelabs Technologies, Inc. | Method of treating viral infections with aryl macrocyclic compounds |
| AU4803393A (en) * | 1992-08-06 | 1994-03-03 | Genelabs Technologies, Inc. | Inhibition and treatment of infection by enveloped virus with calix(n) arene compounds |
| AU1545395A (en) * | 1994-01-24 | 1995-08-08 | Stephen J. Harris | Calixarene-based compounds having antibacterial, antifungal, anticancer-hiv activity |
| EP0883432A1 (de) * | 1996-02-28 | 1998-12-16 | Transdiffusia S.A. | Verfahren zur rückgewinnung von flüchtigen niedermolekularen verbindungen |
| JPH11209740A (ja) * | 1998-01-19 | 1999-08-03 | Kurita Water Ind Ltd | ハロゲン化エチレン化合物の分離剤 |
-
2002
- 2002-06-12 DE DE10226099A patent/DE10226099A1/de not_active Withdrawn
-
2003
- 2003-06-06 AU AU2003245917A patent/AU2003245917A1/en not_active Abandoned
- 2003-06-06 EP EP03737999A patent/EP1526910A2/de not_active Withdrawn
- 2003-06-06 WO PCT/EP2003/005957 patent/WO2003105990A2/de not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO03105990A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003245917A8 (en) | 2003-12-31 |
| WO2003105990A2 (de) | 2003-12-24 |
| AU2003245917A1 (en) | 2003-12-31 |
| DE10226099A1 (de) | 2004-01-08 |
| WO2003105990A3 (de) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0533727B1 (de) | ADSORPTIONSMATERIAL ZUR SELEKTIVEN ENTFERNUNG VON LDL ODER/UND vLDL | |
| DE3115608C2 (de) | Vorrichtung für die Adsorption von Blutproteinen | |
| Hostettmann | Saponins with molluscicidal activity from Hedera helixL | |
| DE69605395T2 (de) | Vorrichtung zum extrakoporealen Entfernen von Toxinen, insbesondere Zytokinen | |
| DE69424339T2 (de) | Positiv geladene Membran aus Polyvinylidenfluorid | |
| DE2746942A1 (de) | Neue psoralenderivate | |
| DE69834651T2 (de) | Filtermaterial zur entfernung von weissen blutkörperchen | |
| DE4331358A1 (de) | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten | |
| DE60009723T2 (de) | Verfahren zur abtrennung von lactonhaltigen verbindungen mit hohem molekulargewicht | |
| DE10045434A1 (de) | Adsorbens mit unterschiedlich modifizierten Oberflächenbereichen, Verfahren zu dessen Herstellung und Verwendung davon | |
| DE69218477T2 (de) | Medizinisches Material, Verfahren zu seiner Herstellung und medizinisches Gerät | |
| EP0548794A2 (de) | Polyaspartamidderivate als Adsorptionsmittel für Gallensäuren, mit Gallensäuren beladene Polyaspartamidderivate und Verfahren zu deren Herstellung sowie deren Anwendung als Arzneimittel | |
| DE10011481A1 (de) | Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Verwendung des Adsorbens zur Herstellung eines Adsorbers und Adsorber mit dem Adsorbens | |
| DE69330458T2 (de) | Verfahren zur gewinnung eines hochreinen factor viii/von willebrand faktor komplexes durch anionenaustauschchromatographie | |
| DE3926539A1 (de) | Verwendung von tentakel-kationenaustauschern zur selektiven eliminierung von low-density-lipoproteinen (ldl), fibrinogen und/oder harnstoff aus fluessigkeiten | |
| EP1132129A1 (de) | Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers | |
| EP1526910A2 (de) | Filtermaterial f r toxine, bakterien, viren und andere physi ologische schadstoffe | |
| DE69219384T2 (de) | Packungen mit über Spacer an Träger gebundenem Protein | |
| EP1104674A1 (de) | O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung | |
| DE60131710T2 (de) | Verfahren zur Adsorption und Entfernung, und Verwendung eines Adsorbers für endogene Cannabinoide | |
| DE10147463A1 (de) | Verfahren zur Aufreinigung von Vollblut | |
| CN106928309B (zh) | 一种螺旋甾碱烷型糖苷生物碱及其制备方法与用途 | |
| DE69525297T2 (de) | Adsorbens fuer ketoamine enthaltende proteine | |
| DE3715447C2 (de) | Verfahren zur Herstellung einer Mischung von O-(beta-Hydroxyethyl)-diosminen | |
| CN106939031B (zh) | 一种螺旋甾碱烷型糖苷生物碱及其制备方法与用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050112 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PLT PATENTS & LICENCE TRADING LTD. |
|
| 17Q | First examination report despatched |
Effective date: 20080618 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20081230 |